Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|171|5|720-725

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.5, 2015-12, pp. : 720-725

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E86-E91

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 344-354

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 820-823

John Wiley & Sons Inc

Access to resources Recommend Favorite